Berner Juan Enrique, Nicolaides Marios, Ali Stephen, Pafitanis Georgios, Preece Jane, Hopewell Sally, Nanchahal Jagdeep
Kellogg College, University of Oxford, Oxford, UK.
The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK.
Rheumatology (Oxford). 2024 Dec 1;63(12):3221-3233. doi: 10.1093/rheumatology/keae176.
To evaluate the efficacy of pharmacological interventions for treating early-stage, pain predominant, adhesive capsulitis, also known as frozen shoulder.
We performed a systematic review in accordance with Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. Searches were conducted on MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials on 24 February 2022. Outcomes were shoulder pain, shoulder function and range of movement. Synthesis involved both qualitative analysis for all studies and pairwise meta-analyses followed by a network meta-analysis for randomized controlled trials (RCTs).
A total of 3252 articles were found, of which 31 met inclusion criteria, and 22 of these were RCTs. IA injection of CS (8 RCTs, 340 participants) and IA injection of platelet-rich plasma (PRP) (3 RCTs, 177 participants) showed benefit at 12 weeks compared with physical therapy in terms of shoulder pain and function, while oral NSAIDs (2 RCTs, 44 participants) and IA injection of hyaluronate (2 RCTs, 42 participants) did not show a benefit. Only IA PRP showed benefit over physical therapy for shoulder range of movement.
These results shows that IA CS and IA PRP injections are beneficial for early-stage frozen shoulder. These findings should be appraised with care considering the risk of bias, heterogeneity and inconsistency of the included studies. We believe that research focused on early interventions for frozen shoulder could improve patient outcomes and lead to cost-savings derived from avoiding long-term disability. Further well-designed studies comparing with standardized physical therapy or placebo are required to improve evidence to guide management.
评估药物干预治疗早期以疼痛为主的粘连性关节囊炎(又称肩周炎)的疗效。
我们按照系统评价和Meta分析的首选报告项目(PRISMA)指南进行了系统评价。于2022年2月24日在MEDLINE、EMBASE和Cochrane对照试验中央注册库进行检索。结局指标为肩部疼痛、肩部功能和活动范围。综合分析包括对所有研究的定性分析以及对随机对照试验(RCT)进行成对Meta分析,随后进行网状Meta分析。
共检索到3252篇文章,其中31篇符合纳入标准,其中22篇为RCT。与物理治疗相比,关节内注射皮质类固醇(CS)(8项RCT,340名参与者)和关节内注射富血小板血浆(PRP)(3项RCT,177名参与者)在12周时在肩部疼痛和功能方面显示出益处,而口服非甾体抗炎药(2项RCT,44名参与者)和关节内注射透明质酸(2项RCT,42名参与者)未显示出益处。仅关节内注射PRP在肩部活动范围方面比物理治疗更有益。
这些结果表明,关节内注射CS和关节内注射PRP对早期肩周炎有益。考虑到纳入研究的偏倚风险、异质性和不一致性,应对这些发现谨慎评估。我们认为,专注于肩周炎早期干预的研究可以改善患者预后,并通过避免长期残疾节省成本。需要进一步设计良好的研究,与标准化物理治疗或安慰剂进行比较,以改善证据指导管理。